media – Page 117 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Weak brain circuit connection found to influence overeating and obesity

Why can some people easily stop eating when they are full and others can’t, which can lead to obesity? A Northwestern Medicine study has found one reason may be a newly discovered structural connection between two regions in the brain that appears to be involved in regulating feeding behavior. These regions involve the sense of smell and behavior motivation. The weaker the connection between these two brain regions, the higher a person’s Body Mass Index (BMI), the Northwestern scientists report. The investigators discovered this connection between the olfactory tubercle, an olfactory cortical region, which is part of the brain’s reward system, and a midbrain region called the periaqueductal gray (PAG), involved in motivated behavior in response to negative feelings like pain and threat and potentially in suppression of eating. The study will be published May 16 in the Journal of Neuroscience. Previous research at Northwestern by co-author Thorsten Kahnt, now ...
- Source: drugdu
- 113
- May 20, 2024
EmpiRx Announces New AI-Powered Platform as Part of Push to Change PBMs

Mike Hollan The platform will use AI technology to provide pharmacists with more tools. The relationship between the pharma industry, pharmacists, and customers continues to evolve. EmpiRx Health, a PBM company headquartered in NJ, announced that it is launching a new AI-powered platform.1 The new platform is called Clinically, and it will use AI technology to help pharmacists with claims adjudication, clinical reviews, and other features that EmpiRx says will put the pharmacists at the center of the PBM model. In a press release, EmpiRx’s CEO Danny Sanchez said, “Our new Clinically platform clearly demonstrates EmpiRx Health’s strong commitment to transforming the pharmacy care industry by creating the PBM of the future – one that’s already providing the highest quality service to customers, patients, and advisor partners. This PBM revolution was long overdue. Far from helping plan sponsors to manage and lower drug costs, the traditional PBM model, which prioritizes ...
- Source: drugdu
- 98
- May 20, 2024
The View from Investors

Mike Hollan Industry experts gather to discuss the current investor market and how the IRA may impact the industry in the coming years. Financial Times US Pharma and Biotech Summit 2024After the post-Covid crash, investors are seeing promising trends in the pharma and biotech industry in 2024. The following speakers presented a panel discussing the industry from an investors perspective at the Financial Times’ US Pharma and Biotech Summit 2024 in New York City: Harmeet Dhillon, head of public policy at GSK; Amit Sinha, chief investment officer at Goldman Sachs; Darius Lakdawalla, quintiles chair in pharmaceutical development at the University of Southern California; and Johanna Grossman, head of healthcare and US life sciences at the US Stock Exchange. Oliver Barnes, a US pharmaceutical and biotech correspondent for the Financial Times moderated the event. The conversation focused on both the current state of the industry and where each of the speakers ...
- Source: drugdu
- 133
- May 20, 2024
USFDA concludes inspection of Indoco’s Rabale facility

Indoco Remedies announced that the United States Food and Drug Administration (USFDA) successfully completed inspection of its API Kilo Lab manufacturing facility at Rabale, Navi Mumbai and Indoco Analytical Solutions (IAS) division. The inspection concluded with zero Form 483 observations. “We remain committed to ensuring the safety and efficacy of our products while maintaining the trust of our customers and stakeholders”, said Aditi Panandikar, MD, Indoco Remedies. https://www.expresspharma.in/usfda-concludes-inspection-of-indocos-rabale-facility/
- Source: drugdu
- 103
- May 20, 2024
Zydus, MSN partner to license and supply Cabozantinib Tablets for the US

Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market. As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the product in the US market. MSN was the first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX. The total addressable market opportunity of Cabozantinib Tablets in the US is approximately $ 1,464 million. https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-ipsen-enter-exclusive-licensing-agreement
- Source: drugdu
- 129
- May 20, 2024
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop

Ionis and Biogen are halting the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after it failed to show improvement in patients in a Phase I/II study. Data from the 99-patient ALSpire study (NCT04494256) demonstrated that BIIB105 failed to significantly reduce neurodegeneration or improve functional measures such as breathing. BIIB105, an investigational antisense oligonucleotide was designed to reduce the expression of ataxin-2 (ATXN2) protein. Despite demonstrating statistically significant ATXN2 reductions in the study, the drug showed no evidence of clinical benefit in any subgroup evaluated in the study. This marks another setback in the search for new treatments for ALS, a progressive neurodegenerative disease that causes muscle weakness and paralysis. Last month, Amylyx Pharmaceuticals axed its ALS drug Relyvrio (AMX0035) from the market after its Phase III Phoenix trial failed to meet any of its endpoints. However, this trial failure does not mark the end of Ionis and ...
- Source: drugdu
- 106
- May 20, 2024
Roche targets obesity market with early positive trial data

Roche is looking to share in the windfall from the sales in obesity therapies as it announces positive results from the Phase Ib trial of its investigational obesity and type 2 diabetes (T2D) therapy. CT-388 is a once-weekly subcutaneous dual glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. It selectively targets two incretin receptors that control food intake, energy absorption and assimilation. The therapy has a similar mechanism of action as Eli Lilly’s Mounjaro (tirzepatide), which generated $1.81bn in sales in Q1 this year, according to Lilly’s financials. Following today’s news, the Swiss company’s share was up by over 3.5% in trading today on the Swiss stock market. Roche’s market cap is SFr190.6bn ($210.8bn). The placebo-controlled Phase Ib trial (NCT04838405) enrolled approximately 96 overweight or obese participants with or without T2D. The participants in the CT-388 group achieved a mean placebo-adjusted weight loss of 18.8% at 24 ...
- Source: drugdu
- 109
- May 20, 2024
RUSSIAN HEALTH CARE WEEK 2024

Organiser:ZAO Time:2- 6 Dec. 2024 address：Krasnopresnenskaya naberezhnaya, 14, Moscow, Russia Exhibition hall: Expocentre Exhibition Center Product range: Diagnostic equipment: X-ray diagnostic equipment, ultrasonic diagnostic equipment, functional examination equipment, endoscopy equipment, nuclear medicine equipment, experimental diagnostic equipment, pathological diagnostic equipment, diagnostic imaging equipment, chromatographic analyzer, consulting room analyzer, dialysis and transplant surgery Treatment equipment: clinical radiology equipment; Clinical testing equipment and reagents, ward nursing equipment, surgery equipment, radiotherapy equipment, nuclear medicine treatment equipment, physical and chemical equipment, laser equipment, dialysis treatment equipment, temperature freezing equipment, first aid equipment Auxiliary equipment: disinfection and sterilization equipment, refrigeration equipment, central suction and oxygen supply system, air conditioning equipment, pharmaceutical machinery and equipment, blood bank equipment, medical data processing equipment, medical video and photography equipment, medical air pump system cosmetic equipment; Ophthalmic equipment and treatment technology and materials, dental equipment and instruments, dental repair systems and instruments, oral plastic surgery materials and tools, dental lasers, ...
- Source: drugdu
- 155
- May 20, 2024
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells

Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations involved, typically require invasive biopsies, which can cause harm. Now, a research team has developed a new method to utilize ultrasound for gently extracting this genetic information. Researchers at the University of Alberta (Edmonton, AB, Canada) have been investigating the use of intense ultrasound in releasing biological indicators of disease, or biomarkers, from cells. These biomarkers include elements like miRNA, mRNA, DNA, and various genetic mutations, all of which are critical for identifying the cancer type and guiding treatment decisions. The ultrasound technique releases these biomarkers from the cells into the bloodstream, where they reach concentrations high enough to be detected. This enables oncologists to identify and track the cancer’s status or response to treatment through blood samples instead of ...
- Source: drugdu
- 92
- May 17, 2024
New DNA Origami Technique to Advance Disease Diagnosis

DNA origami is a method used to create nanostructures with exceptional precision, utilizing DNA strands as the foundational building blocks. These structures, however, are inherently fragile and prone to disintegration under biological conditions, such as fluctuations in temperature or the presence of certain enzymes in living organisms. To address this vulnerability, researchers have now devised an innovative method to both customize and strengthen DNA origami, offering the potential to advance drug delivery and disease diagnostics. A team of scientists from the universities of Portsmouth (Portsmouth, UK) and Leicester (Leicester, UK) has pioneered a novel approach to reinforce these origami structures, making them both stronger and more adaptable through a process they call triplex-directed photo-cross-linking. This technique involves the strategic addition of new nucleotide sequences to the DNA during the design phase. These sequences are the basic building blocks of DNA and act as attachment points for functional molecules, enhancing the ...
- Source: drugdu
- 90
- May 17, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.